Navigation Links
University Hospitals Case Medical Center testing gene therapy for Alzheimer's disease
Date:1/7/2010

University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain. University Hospitals (UH) is the only site in the Midwest for the study. The study is sponsored by a contract to Case Western Reserve University from the Alzheimer's Disease Cooperative Study (ADCS) through a grant from the National Institute on Aging in association with Ceregene, Inc., which developed and will provide the active agent CERE-110.

NGF is a naturally occurring protein that may prevent nerve cells in the brain from dying and may help these cells function better. During the study, CERE-110 will be injected by a neurosurgeon into the nucleus basalis of Meynert, an area of the brain where nerve cells die in patients with AD.

"A small study in humans showed that CERE-110 was generally safe and well-tolerated," said Alan J. Lerner, M.D., principal investigator of the Cleveland site, director of the UH Neurological Institute Memory and Cognition Center, and a professor of neurology at the Case Western Reserve University School of Medicine.

The Phase 2 study will evaluate whether the therapy is safe for a larger group of patients and whether it helps the symptoms of AD. In total, 50 patients will be enrolled throughout the United States and UH aims to enroll at least five patients in this study.

"Should the clinical development of this therapy be successful, CERE-110 could offer the possibility of delaying the course of Alzheimer's disease, a real improvement over existing therapies," said Dr. Lerner. "This would not be a cure for AD, but a way of slowing it down."

Participants in the Phase 2 study will be randomly placed into one of two treatment groups, with half of the subjects receiving CERE-110 and the other half receiving placebo surgery. At the completion of the trial, subjects in the placebo arm may have the opportunity to receive the active treatment if the product seems safe and effective.


'/>"/>

Contact: George Stamatis
george.stamatis@UHhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. A study by the MUHC and McGill University opens a new door to understanding cancer
2. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
3. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
4. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
5. Binghamton University researchers investigate evolving malaria resistance
6. Antioxidant to retard wrinkles discovered by Hebrew University researcher
7. Society for General Microbiology 161st Meeting, University of Edinburgh
8. Boston University biomedical engineers find chink in bacterias armor
9. KAUST and American University in Cairo to collaborate on research and academic development
10. UNH becomes first university in nation to use landfill gas as primary energy source
11. University of Minnesota study refutes belief that black men have more aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
Breaking Biology Technology: